120 related articles for article (PubMed ID: 10607691)
1. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia.
Cimino G; Elia L; Rapanotti MC; Sprovieri T; Mancini M; Cuneo A; Mecucci C; Fioritoni G; Carotenuto M; Morra E; Liso V; Annino L; Saglio G; De Rossi G; Foà R; Mandelli F
Blood; 2000 Jan; 95(1):96-101. PubMed ID: 10607691
[TBL] [Abstract][Full Text] [Related]
2. Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia.
Elia L; Gottardi E; Floriddia G; Grillo R; Ciambelli F; Luciani M; Chiusolo P; Invernizzi R; Meloni G; Foà R; Saglio G; Cimino G
Leukemia; 2004 Nov; 18(11):1824-30. PubMed ID: 15318246
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation.
Uckun FM; Herman-Hatten K; Crotty ML; Sensel MG; Sather HN; Tuel-Ahlgren L; Sarquis MB; Bostrom B; Nachman JB; Steinherz PG; Gaynon PS; Heerema N
Blood; 1998 Aug; 92(3):810-21. PubMed ID: 9680349
[TBL] [Abstract][Full Text] [Related]
4. Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
Laczika K; Mitterbauer G; Mitterbauer M; Knöbl P; Schwarzinger I; Greinix HT; Rabitsch W; Fonatsch C; Mannhalter C; Lechner K; Jaeger U
Leuk Lymphoma; 2001; 42(5):923-31. PubMed ID: 11697647
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23).
Hilden JM; Frestedt JL; Moore RO; Heerema NA; Arthur DC; Reaman GH; Kersey JH
Blood; 1995 Nov; 86(10):3876-82. PubMed ID: 7579356
[TBL] [Abstract][Full Text] [Related]
6. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia.
Cimino G; Elia L; Rivolta A; Rapanotti MC; Rossi V; Alimena G; Annino L; Canaani E; Lo Coco F; Biondi A
Br J Haematol; 1996 Mar; 92(3):659-64. PubMed ID: 8616032
[TBL] [Abstract][Full Text] [Related]
8. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.
Guerrasio A; Pilatrino C; De Micheli D; Cilloni D; Serra A; Gottardi E; Parziale A; Marmont F; Diverio D; Divona M; Lo Coco F; Saglio G
Leukemia; 2002 Jun; 16(6):1176-81. PubMed ID: 12040450
[TBL] [Abstract][Full Text] [Related]
9. Serial analysis of MLL-AF4 chimeric message through successful bone marrow transplantation in a patient with t(4;11)-positive infant-ALL.
Tabata Y; Hibi S; Maruyama-Tabata H; Tsunamoto K; Todo S; Sawada T; Okamura T; Kawa-Ha K; Imashuku S
Am J Hematol; 2000 Jul; 64(3):203-5. PubMed ID: 10861817
[TBL] [Abstract][Full Text] [Related]
10. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
11. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction.
Mitterbauer G; Zimmer C; Pirc-Danoewinata H; Haas OA; Hojas S; Schwarzinger I; Greinix H; Jäger U; Lechner K; Mannhalter C
Br J Haematol; 2000 Jun; 109(3):622-8. PubMed ID: 10886213
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.
Morschhauser F; Cayuela JM; Martini S; Baruchel A; Rousselot P; Socié G; Berthou P; Jouet JP; Straetmans N; Sigaux F; Fenaux P; Preudhomme C
J Clin Oncol; 2000 Feb; 18(4):788-94. PubMed ID: 10673520
[TBL] [Abstract][Full Text] [Related]
14. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: a single center study.
Mitterbauer M; Mitterbauer-Hohendanner G; Sperr WR; Kalhs P; Greinix HT; Fonatsch C; Haas OA; Jäger U; Mannhalter C; Lechner K
Leuk Lymphoma; 2004 May; 45(5):971-7. PubMed ID: 15291357
[TBL] [Abstract][Full Text] [Related]
15. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
16. Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission.
Janssen JW; Ludwig WD; Borkhardt A; Spadinger U; Rieder H; Fonatsch C; Hossfeld DK; Harbott J; Schulz AS; Repp R
Blood; 1994 Dec; 84(11):3835-42. PubMed ID: 7949140
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction.
Lee S; Kim DW; Cho B; Kim YJ; Kim YL; Hwang JY; Park YH; Shin HJ; Park CY; Min WS; Kim HK; Kim CC
Br J Haematol; 2003 Jan; 120(1):145-53. PubMed ID: 12492591
[TBL] [Abstract][Full Text] [Related]
18. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of minimal residual leukemia in patients with MLL-AF9 positive acute myeloid leukemia by RT-PCR.
Mitterbauer G; Zimmer C; Fonatsch C; Haas O; Thalhammer-Scherrer R; Schwarzinger I; Kalhs P; Jaeger U; Lechner K; Mannhalter C
Leukemia; 1999 Oct; 13(10):1519-24. PubMed ID: 10516752
[TBL] [Abstract][Full Text] [Related]
20. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
